Effectiveness and safety of switching to biosimilar infliximab and etanercept in patients with psoriasis

Lund Tamara; Sand Carsten; Gniadecki Robert; Thomsen Simon F.

首页> 外文期刊>Dermatologic therapy >Effectiveness and safety of switching to biosimilar infliximab and etanercept in patients with psoriasis

【24h】

Effectiveness and safety of switching to biosimilar infliximab and etanercept in patients with psoriasis

机译：牛皮癣患者的生物纤维单纤维生素和依赖替替替替辛的有效性和安全性

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Dermatologic therapy》 |2019年第3期|共2页
作者
Lund Tamara; Sand Carsten; Gniadecki Robert; Thomsen Simon F.;
展开▼
作者单位

Department of DermatologyBispebjerg HospitalCopenhagen Denmark;

Department of DermatologyBispebjerg HospitalCopenhagen Denmark;

Department of DermatologyBispebjerg HospitalCopenhagen Denmark;

Department of DermatologyBispebjerg HospitalCopenhagen Denmark;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类皮肤病学与性病学;
关键词

相似文献

外文文献
中文文献
专利

1. Effectiveness and safety of switching to biosimilar infliximab and etanercept in patients with psoriasis [J] . Lund Tamara, Sand Carsten, Gniadecki Robert, Dermatologic therapy . 2019,第3期

机译：牛皮癣患者的生物纤维单纤维生素和依赖替替替替辛的有效性和安全性
2. Multiple switches between GP GP 2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque‐type psoriasis: 30‐week results from the phase 3, confirmatory EGALITY EGALITY study [J] . Gerdes S., Tha?i D., Griffiths C.E.M., Journal of the European Academy of Dermatology and Venereology: JEADV . 2018,第3期

机译：GP GP 2015之间的多个交换机，依赖替斯科生物酸碱单位，发起者产品不会影响慢性斑块型牛皮癣患者的疗效，安全性和免疫原性：30周的阶段3，鉴定的Egality Egality研究
3. Safety and effectiveness of switching from infliximab to etanercept in patients with rheumatoid arthritis: Results from a large Japanese postmarketing surveillance study [J] . KoikeT., HarigaiM., InokumaS., Rheumatology international. . 2012,第6期

机译：类风湿关节炎患者从英夫利昔单抗转为依那西普的安全性和有效性：一项大型日本上市后监测研究的结果
4. N-linked Glycan Profile Comparison Between the Innovator and a Biosimilar Etanercept [C] . Ying Qing Yu, Asish Chakraborty, Mark Hillard, American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2013

机译：创新者与BioSimilar entanErcept之间的N-Linked Glycan简介比较
5. A Cost-utility Analysis of Biosimilar Infliximab Compared to Reference Infliximab in Adult Switch Patients with Crohn's Disease: A Canadian Analysis [D] . Hughes, Avery. 2018

机译：生物纤维生素infiximab的成本实用性分析与成人交换患者参考incriximab患者克罗恩病患者：加拿大分析
6. Safety and effectiveness of switching from infliximab to etanercept in patients with rheumatoid arthritis: results from a large Japanese postmarketing surveillance study [O] . Takao Koike, Masayoshi Harigai, Shigeko Inokuma, -1

机译：类风湿关节炎患者从英夫利昔单抗转为依那西普的安全性和有效性：一项大型日本上市后监测研究的结果
7. Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis:30-week results from the phase 3, confirmatory EGALITY study [O] . Gerdes, S, Thaçi, D, Griffiths, C E M, 2017

机译：Gp2015（一种依那西普生物仿制药）与原始产品之间的多次转换不会影响慢性斑块型银屑病患者的疗效，安全性和免疫原性：第3阶段的30周结果，验证性EGaLITY研究

Effectiveness and safety of switching to biosimilar infliximab and etanercept in patients with psoriasis

著录项

相似文献

相关主题

期刊订阅